Group 1 - The core viewpoint is that Zhao Bei, a fund manager, oversees seven funds, with the best quarterly performance being a decline of 11.44% for the Industrial Bank Pension Industry Stock A fund by the end of Q4 2025 [1] - During Zhao Bei's tenure as the manager of the Industrial Bank Healthcare Stock fund, the cumulative return was 192.7%, with an average annualized return of 10.08% [1] - The fund had 95 instances of stock adjustments, achieving a profit in 65 cases, resulting in a win rate of 68.42% [1] Group 2 - A notable stock adjustment example is the investment in Yingke Medical, which was bought in Q1 2020 and sold in Q1 2021, yielding an estimated return of 812.18% during the holding period, with a revenue growth of 17.37% from 2020 to 2021 [2] - Another example is the investment in Lepu Medical, purchased in Q4 2015 and sold in Q3 2020, which resulted in an estimated return of 99.44%, while the net profit increased by 245.93% from 2015 to 2020 [3] - A less successful case involved Aier Eye Hospital, bought in Q2 2021 and sold in Q2 2024, resulting in an estimated return of -63.63%, despite a net profit growth of 53.06% from 2021 to 2024 [4]

Core Viewpoint - The AI Fund ICBC Pension Industry Stock A (001171) reported a profit of 111 million yuan for the first half of 2025, with a weighted average profit per fund share of 0.0911 yuan, and a net asset value growth rate of 6.75% during the reporting period [3] Fund Performance - As of September 3, the fund's net value growth rates were 18.94% over the past three months, 25.95% over the past six months, 38.09% over the past year, and 5.03% over the past three years, ranking 42/54, 43/54, 45/53, and 30/47 among comparable funds respectively [6] Fund Valuation - As of June 30, 2025, the fund's weighted price-to-earnings ratio (TTM) was approximately 39.95 times, with a weighted price-to-book ratio (LF) of about 4.09 times, and a weighted price-to-sales ratio (TTM) of approximately 5.39 times, compared to the average of comparable funds [12] Growth Metrics - For the first half of 2025, the fund's weighted revenue growth rate (TTM) was 0.03%, and the weighted net profit growth rate (TTM) was -0.01%, with a weighted annualized return on equity of 0.1% [19] Fund Holdings and Structure - As of June 30, 2025, the fund had a total of 80,600 holders, with a total of 1.171 billion shares held. Management employees held 1.6579 million shares (0.14%), institutions held 17.96%, and individual investors held 82.04% [36] - The fund's top ten holdings included companies such as Heng Rui Pharmaceutical, Kelun Pharmaceutical, and Mindray Medical [41]